Business Context and Reporting Period
This Form 6-K filing by GSK plc, a global biopharma company, was issued on May 1, 2026. The report serves as a notification to the market regarding the company's issued share capital and total voting rights as of April 30, 2026, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial results report.
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It solely updates the share capital structure as of the reporting date.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It includes a standard corporate description stating GSK's purpose to unite science, technology, and talent to get ahead of disease.
Important Facts for Investors
- Total Issued Share Capital: 4,316,202,660 Ordinary Shares of 31.25 pence each as of April 30, 2026.
- Treasury Shares: 261,378,286 Ordinary Shares were held in Treasury.
- Total Voting Rights: 4,054,824,374 (calculated as issued shares minus treasury shares).
- Regulatory Use: The total voting rights figure is the denominator for shareholders to determine notification requirements under FCA rules.
- Contact for Notifications: company.secretary@gsk.com.